| Pharmaceutical Information |
| Drug Name |
Exenatide |
| Drug ID |
BADD_D00862 |
| Description |
Exenatide is a glucagon-like peptide-1 (GLP-1) analog[Label]. It functions to activate the GLP-1 receptor and increases insulin secretion, decrease glucagon secretion, and slow gastric emptying to improve glycemic control[Label]. Exenatide was given FDA approval on April 28, 2005[L6106]. |
| Indications and Usage |
Exenatide is indicated for improving glycemic control in adults with type 2 diabetes mellitus along with diet and exercise[Label]. |
| Marketing Status |
approved; investigational |
| ATC Code |
A10BJ01 |
| DrugBank ID |
DB01276
|
| KEGG ID |
D04121
|
| MeSH ID |
D000077270
|
| PubChem ID |
45588096
|
| TTD Drug ID |
D00YVF
|
| NDC Product Code |
52416-125; 0310-6540; 41524-0003; 69766-078; 68067-0397; 0310-6512; 0310-6524; 52416-105; 0406-7310; 59149-004 |
| UNII |
9P1872D4OL
|
| Synonyms |
Exenatide | Bydureon | ITCA 650 | AC 2993 LAR | Exendin-4 | Ex4 Peptide | Peptide, Ex4 | Exendin 4 | Byetta | AC 2993 |
|
| Chemical Information |
| Molecular Formula |
C184H282N50O60S |
| CAS Registry Number |
141758-74-9 |
| SMILES |
CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(CCCCN
)C(=O)NC(CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCCC3C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(
C)C(=O)N4CCCC4C(=O)N5CCCC5C(=O)N6CCCC6C(=O)NC(CO)C(=O)N)NC(=O)C(CC7=CC=CC=C7)NC(
=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C(C)C)NC(=O)C(C)NC(=O)C(CCC(=O)O)NC(=O)C(
CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(CCSC)NC(=O)C(CCC(=O)N)NC(=O)C(CCCCN)NC(=O)C(CO
)NC(=O)C(CC(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC8=CC=CC=C8)NC
(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC9=CNC=N9)N |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
